TB Alternative Assets Ltd. Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

TB Alternative Assets Ltd. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 9,168 shares of the biopharmaceutical company's stock, valued at approximately $2,476,000.

Several other institutional investors have also recently added to or reduced their stakes in ALNY. Larson Financial Group LLC increased its stake in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 73 shares during the last quarter. Park Square Financial Group LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $28,000. Whipplewood Advisors LLC increased its stake in Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the last quarter. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Finally, Colonial Trust Co SC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 2.3%

NASDAQ:ALNY opened at $300.83 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The business's 50 day moving average is $264.17 and its two-hundred day moving average is $257.20. Alnylam Pharmaceuticals, Inc. has a 52 week low of $150.72 and a 52 week high of $310.22. The company has a market cap of $39.22 billion, a PE ratio of -138.63 and a beta of 0.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the previous year, the company posted ($0.16) earnings per share. The firm's revenue was up 20.2% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on ALNY. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research note on Friday, April 11th. HC Wainwright restated a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $280.00 to $328.00 in a research note on Monday, March 24th. Royal Bank of Canada increased their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. Finally, Citigroup increased their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $319.17.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer now owns 48,948 shares of the company's stock, valued at $14,978,088. This trade represents a 28.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.